Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Everest Medicines Limited

雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

NOTICE OF EXTRAORDINARY GENERAL MEETING

The extraordinary general meeting will be held by way of virtual meeting via the Online Platform which can be accessed from any location with connection to the internet. Shareholders of the Company need not to attend the extraordinary general meeting in person.

NOTICE IS HEREBY GIVEN that the extraordinary general meeting (the "**EGM**" or "**Extraordinary General Meeting**") of Everest Medicines Limited (the "**Company**") will be held on Tuesday, 24 February 2026 at 10:00 a.m. by way of virtual meeting via the Online Platform for the following purposes:

1. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

   "**THAT**

   (a) the commercialization service agreement entered into by Everest Medicines (China) Co., Ltd 雲頂新耀醫藥科技有限公司 and Hasten Biopharmaceutical Co., Ltd. dated 11 December 2025 (the "**Commercialization Service Agreement**") and the transactions contemplated thereunder, be and are hereby approved, ratified and confirmed; and

   (b) any one or more directors of the Company (the "**Directors**"), with the exception of Mr. Wei Fu, be and is hereby authorized for and on behalf of the Company to execute, and where required, to affix the common seal of the Company to, any documents, instruments or agreements, and to do any acts and things deemed by him or her to be necessary, expedient or appropriate in order to give effect to and implement the transactions contemplated under the Commercialization Service Agreement."

2. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT**

(a) the grant of 530,303 awards (the "**Awards**") to Mr. Yifang Wu (the "**Proposed Award Grant**'") in accordance with the terms of the Pre-IPO employee equity plan adopted on 25 December 2018 (the "**Pre-IPO ESOP**"), subject to all applicable laws, rules, regulations and the applicable grant letter, be hereby approved and confirmed; and

(b) any one or more of the Directors, with the exception of Mr. Wu, be authorised to exercise the powers of the Company to allot and issue the ordinary shares of the Company pursuant to the Proposed Award Grant under the Pre-IPO ESOP, such that the award shares to be issued pursuant to the Proposed Award Grant shall rank pari passu in all respects among themselves and with the existing ordinary shares in issue at the date of the allotment and issuance of the award shares, and that he/she, be and is hereby authorised to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 1(a) above."

3. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT**

That the adoption of the 2026 Share Scheme (the "**2026 Share Scheme**") proposed by the board of Directors (the "**Board**"), a copy of which is produced to this meeting marked "A" and signed by the Chairman of the meeting for the purpose of identification, with the Scheme Mandate Limit (as defined in the 2026 Share Scheme) of 10% of the total issued and outstanding Shares (excluding any treasury shares) as at the date of the Shareholders' approval of the 2026 Share Scheme, be and is hereby approved and adopted, and the Board and the Scheme Administrator (as defined in the 2026 Share Scheme) be and are hereby authorised to grant the awards ("**2026 Awards**"), and do all such acts and execute all such documents as the Board or the Scheme Administrator may consider necessary or expedient in order to give full effect to the 2026 Share Scheme."

4. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT, conditional upon the passing of ordinary resolution 3,** the Service Provider Sublimit (as defined in the 2026 Share Scheme, and which includes grants to Service Provider Participants under any other share schemes of the Company) of 0.5% of the total issued and outstanding Shares (excluding any treasury shares) as at the date of the Shareholders' approval of the 2026 Share Scheme be and is hereby approved and adopted.

Ordinary resolution 3 is not conditional upon the passing of ordinary resolution 4, but ordinary resolution 4 is conditional upon the passing of ordinary resolution 3. In the event that ordinary resolution 3 is passed but ordinary resolution 4 is not passed, the Company will adopt the 2026 Share Scheme but the Board shall alter the Scheme to remove references to the grant of 2026 Awards to Service Providers. In the event that ordinary resolution 4 is passed but ordinary resolution 3 is not passed, the 2026 Share Scheme will not be adopted."

By Order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 4 February 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.

Notes:

1. The EGM will be a virtual meeting. All shareholders of the Company (the "**Shareholders**") can attend, participate and vote at the EGM by accessing to the website at (https://meetings.computershare.com/everestmed_2026EGM) (the "**Online Platform**"). Shareholders are reminded that physical attendance in person at the EGM is NOT necessary. Shareholders joining the EGM using the Online Platform will be counted towards the quorum and they will be able to cast their votes and submit questions through the Online Platform.

2. Details regarding EGM arrangements and login access for joining the EGM through the Online Platform are provided on the notification letter to be despatched together with the Company's circular dated 4 February 2026 (the "**Circular**") and related documents. Shareholders attend the EGM are reminded to read the "GUIDANCE FOR THE EGM" set out in the Circular prior to joining the EGM.

3. All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.

4. Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint any number of proxies to attend and vote instead of him. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present or by proxy shall be entitled to one vote for each share held by him.

5. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company's share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the meeting or the adjourned meeting (as the case may be). This email address is provided solely for receiving proxy forms relating to the EGM and shall not be used for any other purposes.

6. The record date for determining the Shareholders' eligibility for attending and voting at the EGM is Tuesday, 24 February 2026. For determining the entitlement to attend and vote at the meeting, the register of members of the Company will be closed from Monday, 16 February 2026 to Tuesday, 24 February 2026, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Extraordinary General Meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Friday, 13 February 2026.

7. Shareholders attending the EGM will be able to raise questions relevant to the proposed resolutions during the EGM using the Online Platform. Prior to the EGM, Shareholders are also welcome to send such questions or matters in writing to the Company's email at ir@everestmedicines.com no later than 6:00 p.m. on Friday, 20 February 2026. The Company will endeavor to address relevant questions in relation to the proposed resolutions at the EGM. However, the Company may not be able to answer all the questions during the time allocated. Unanswered questions may be responded to after the EGM.

8. Treasury shares, if any and registered under the name of the Company, shall have no voting rights at the EGM. For the avoidance of doubt and for the purpose of the Listing Rules, holders of treasury shares of the Company (if any) are not entitled to vote at the Extraordinary General Meeting.

If Shareholders have any questions relating to the EGM, please contact the share registrar of the Company as follows:

Computershare Hong Kong Investor Services Limited
17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong
Tel: (852) 2862 8555
Fax: (852) 2865 0990
Online Enquiries: www.computershare.com/hk/en/online_feedback